AC Immune SA (ACIU) – Company Press Releases
-
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
-
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
-
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
-
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
-
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
-
AC Immune Announces Pricing of Underwritten Offering of Common Shares
-
AC Immune Announces Pricing of Underwritten Offering of Common Shares
-
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
-
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
-
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
-
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
-
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
-
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
-
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
-
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
-
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
-
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
-
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
-
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
-
AC Immune SA Appoints New Chief Medical Officer
-
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
-
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
-
AC Immune Holds Annual General Meeting of Shareholders
-
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
-
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
-
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
-
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
-
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
-
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
-
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
-
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
-
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
-
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
-
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
-
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
-
AC Immune to Present at the SVB Securities Global Biopharma Conference
-
AC Immune to Present at the SVB Securities Global Biopharma Conference
-
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
-
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
-
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
-
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
-
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
-
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
-
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
-
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
-
AC Immune to Present at the Jefferies London Healthcare Conference
-
AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
-
AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome
-
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease
-
AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent
Back to ACIU Stock Lookup
